Black, Female Patients with Sarcoidosis More Likely to be Hospitalized
An analysis of national data shows Asian and male patients are at worse risk of mortality, however.
Ixekizumab Significantly Benefits Patients with PsA Plus Nail, DIP Involvement
CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.
Early Guselkumab PsA Response Linked to Long-Term Quality of Life Improvement
Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.
Guselkumab Safety Profile Consistent for Psoriasis, PsA at 5 Years
An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.
Immunosuppressants More Common Among Autoimmune Patients with Severe COVID-19
Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.
Patients of Color with Psoriatic Arthritis Report Worse Depression, Anxiety
New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.
Apremilast Linked to Cardiometabolic, Weight Loss Benefit in Psoriatic Patients at 6 Months
Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.
Etanercept, Adalimumab, JAK Inhibitors Similarly Benefit Rheumatoid Arthritis at 1 Year
A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.
Survey: Psoriatic Arthritis Patients, Rheumatologists Are Aligned on Care Plan
Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.
Jenny Murase, MD: Lebrikizumab’s Evolving Role in Atopic Dermatitis
After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.
Lebrikizumab Improves Hand and Face Dermatitis in Most Patients at 16 Weeks
Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.
4 Oral Biologics in Development for Atopic Dermatitis
Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.
5 Topical Drugs in Development for Atopic Dermatitis
David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.
Patients who Achieve Rapid Onset Itch Relief, Skin Clearance more Satisfied with Eczema Therapy
Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.
Abrocitinib Provides Atopic Dermatitis Clearance Despite Age, Dose at 96 Weeks
Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.
Atopic Dermatitis Biologics are Working, but Precision Care Remains a Goal
Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.
Dupilumab Sustains Atopic Dermatitis Efficacy at 5 Years
An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.
Ruxolitinib Cream 1.5% Significantly Improves Chronic Hand Dermatitis at 4 Weeks
Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.
Lebrikizumab, Corticosteroid Regimen May Benefit Eczema After Dupilumab Discontinuation
Post-hoc data from the phase 3 ADhere trial shows a lebrikizumab regimen may help patients with atopic dermatitis achieve skin clearance they could not with dupilumab.
More Than 95% of Atopic Dermatitis Patients Experience Chronic Itch
A Brazil cross-sectional analysis suggests chronic pruritus is even more common—and burdensome—in atopic dermatitis patients than previously believed.
What Do Atopic Dermatitis Patients Want From Their Therapy?
A new qualitative study of adults with atopic dermatitis shows preference for skin clearance, reduced risk of severe adverse events and a less frequent dosage.
Topical AMTX-100 Proves Safe, Effective for Atopic Dermatitis in Phase 1 Trial
New data show the novel investigative drug from Amytrx was associated with 37% improvement in atopic dermatitis body surface area.
Upadacitinib 30 mg Tops Atopic Dermatitis Systemic Therapies in Meta-Analyses
Updated analysis of more than a dozen clinical trials assessing monotherapy systemic treatment of atopic dermatitis shows upadacitinib's highly prevalent efficacy in clearing skin.
FDA Approves Bi-Monthly Aripiprazole Injection for Schizophrenia, Bipolar Disorder
The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.
Qualitative Research Increasing Throughout Dermatology
The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.
Switching IL-17 Inhibitors Could Improve Psoriasis Management
A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.
Could Dogs Detect COVID-19 in Public?
A California pilot program shows trained dogs may be able to sniff out COVID-19 with 90% specificity.
Alcohol-Assisted Liver Disease Deaths Climbed During COVID-19
National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.
Sleep Health Varies Among Residential, Outpatient Schizophrenia Patients
New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.
EHR Flags May Not Help Emergency Department Nurses with Violent Patients
A qualitative study shows nurses at an urban, academic emergency department vary on whether behavioral flagging results in safer patient interactions.
2 Clarke Drive Cranbury, NJ 08512